Sexually Transmitted Diseases

Jose Arribas, MD, discusses the challenges in the field of long-acting injectable therapy for the treatment, management, and even prevention of HIV.

Subcutaneous implants are 1 promising strategy to address suboptimal adherence to pre-exposure prophylaxis (PrEP) for HIV, and a recent in silico simulation examined pharmacokinetic profiles and safety of tenofovir alafenamide implants.

Brian Woodfall, MD, discusses how long-acting injectables offer a new treatment option for patients with HIV in terms of long-term therapy.

Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, reacts to news of the London patient, the second person cured of HIV infection.

With the proper use of antiretroviral therapy and pre-exposure prophylaxis, the risk of HIV transmission has never been lower. So why do some practitioners hesitate to endorse condomless sex?

Among gay and bisexual men, receipt of PrEP at study enrollment was linked with an increased incidence of STIs, but 25% of participants accounted for 76% of all STIs.

Dolutegravir/lamivudine (Dovato) becomes the first 2-drug, fixed-dose complete treatment for treatment-naive patients with HIV.

Saye Khoo, MD, advocates for a more appropriate, stratified, risk-based approach to prescribing dolutegravir in pregnant women.

Bluma Brenner, PhD, explains the driving factors behind the push for new antiretroviral drugs for HIV treatment.

Contagion® is reflecting on the advancements in treatment and prevention that have been made in infectious diseases while identifying areas that need further improvement to reduce preventable deaths globally.

Although preventing the transmission of HIV from mother to baby is of paramount importance, we cannot overlook other health issues that may crop up later in life for children born to women with HIV.

Brian Woodfall, MD, shares his opinion on some of the biggest advancements in HIV treatment and prevention.

What’s the 411 on 2-1-1?

A 1-month course of rifapentine plus isoniazid is non-inferior to 9 months of isoniazid alone for preventing TB in individuals with HIV, a study reports.

The new single-tablet regimen provides a safe and effective treatment option for patients with HIV.

A neural model suggests the frontal lobe is affected early on in HIV disease and the caudate/striatum area is affected when neurocognitive disorder symptoms develop.

Paul Sax, MD, reacts to the ATLAS and FLAIR studies on long-acting injectable therapy.

A new study found an average decrease of sexual anxiety by 0.27 points when participants were on PrEP compared with before treatment.

Susan Swindells, MBBS, provides an overview of long-acting injectable cabotegravir + rilpivirine for clinicians.

Incorporating clinical pharmacists and stewardship program oversights into PrEP models may improve the rate of retention in care.

A team of doctors at Johns Hopkins has completed the first ever living donor HIV-positive to HIV-positive kidney transplant.

Karin Bosh, PhD, explains why the opioid overdose death rate was higher in 2015 than in 2011 among people with HIV.

With a disproportionate percentage of new HIV infections occurring in young MSM, tech tools may be a way to counter this trend.

A new report indicates that resistant isolates of gonorrhea were detected in more European countries in 2017, and may soon threaten the current recommended treatment protocol.

PrEP isn’t covered by health insurance in Germany, and non-prescription use of the HIV preventive is common. But is it safe?

A survey of MSM and transgender women found that diverse formulations and regimens for PrEP, such as long-acting injectables and “on-demand” PrEP, could increase uptake and persistence.

Julia Marcus, PhD, MPH, provides advice for health care systems looking to implement a model to identify potential PrEP candidates.

Ava Avalos, MD, details the effects of a dolutegravir-based regimen on pregnancy.

There currently aren’t any clear guidelines for how health care providers should handle discrepant—1 positive and 1 negative—HIV test results during pregnancy.

A study of MSM suggests optimizing at-home testing for STIs and HIV could increase rates of testing, while noting a need to balance convenience with educational outreach.